Founded in 1929, Ipsen (IPN) is a leading international biopharmaceutical group, focusing on specialty care. The company develops and produces innovative medicines in 3 major areas: rare diseases, neurosciences and oncology. Ipsen also runs a consumer healthcare business. In general, the company sells over 20 drugs in more than 115 countries worldwide. Ipsen's R&D is focused on its differentiated and innovative technological platforms in the leading biotechnological hubs, based in Cambridge, the US, Oxford, the UK, and Paris-Saclay, France. Headquartered in Paris, the company employs 5,100 specialists. Included to the CAC Mid 60 index, the Ipsen share price (IPN) is set and traded on the Euronext Paris exchange.